Think You Know NASH? A Quiz-Based Challenge on Current and Emerging Management Strategies
Source: Think You Know NASH? A Quiz-Based Challenge on Current and Emerging Management Strategies

Video Module

In this on-demand Webcast, expert faculty review the science of NASH, available diagnostic resources and management strategies, and the latest emerging and investigational therapies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Consider key risk factors for development of NAFLD and the pathophysiologic mechanisms that lead to NASH
  • Identify patients at risk for NASH and employ appropriate testing strategies to confirm diagnosis
  • Critically evaluate data on emerging therapies for NASH, including evidence of reversal of fibrosis, safety data, and their potential utility in the treatment of patients with NASH
CCO Video Modules contain video commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.
 

Faculty

  • Stephen A. Harrison
    MD, COL (Ret.), FAASLD
    Quentin M. Anstee
    BSc, MB BS, PhD, MRCP(UK), FRCP
    Rohit Loomba
    MD, MHSc

Credit Information

  • Release Date:
    November 20, 2017
  • Expiration Date:
    November 19, 2018
  • Physicians:
    maximum of 1.75 AMA PRA Category 1 Credits

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Stephen A. Harrison, MD, COL (Ret.), FAASLD


Visiting Professor of Hepatology
Radcliffe Department of Medicine
University of Oxford
Oxford, United Kingdom

Stephen A. Harrison, MD, COL (Ret.), FAASLD, has disclosed that he has received consulting fees from Capulus, Cirius, Genfit, Echosens, Histoindex, Intercept, Madrigal, NGM Bio, and Perspectum; has received fees for non-CME/CE services from AbbVie, Alexion, and Gilead Sciences; and has an ownership interest in Cirius.
 

Quentin M. Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP


Professor of Experimental Hepatology 
Consultant Hepatologist
Institute of Cellular Medicine
Newcastle University
Newcastle Upon Tyne, United Kingdom

Quentin M. Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP, has disclosed that he has received consulting fees paid to his institution from Abbott, Acuitas Medical, Allergan/Tobira, E3Bio, Galmed, Genfit, Gilead Sciences, Grünenthal, Imperial Innovations, Intercept Pharma Europe Ltd, Inventiva, Janssen, Lilly, MedImmune, NewGen, Novartis, Pfizer, and Raptor Pharma; funds for research support paid to his institution from AbbVie, Allergan/Tobira, AstraZeneca, GlaxoSmithKline, Novartis, and Vertex; active research collaborations (including the EU H2020 EPoS & EU IMI2 LITMUS Consortia*) AbbVie, Antaros Medical,* Allergan/Tobira, AstraZeneca, Boehringer Ingelheim,* Ellegaard Göttingen Minipigs AS,* Exalenz Bioscience,* Genfit,* GlaxoSmithKline, Intercept Pharma Europe,* iXscient,* Lilly,* Nordic Bioscience,* Novartis,* Novo Nordisk A/S,* One Way Liver Genomics SL,* Perspectum Diagnostics,* Pfizer,* sanofi-aventis Deutschland,* SomaLogic,* and Takeda Pharmaceuticals International*; and speaking fees from Abbott, Allergan/Tobira, Falk, Genfit, Gilead Sciences, and Intercept Pharma.
 

Rohit Loomba, MD, MHSc


Director, NAFLD Research Center
Professor of Medicine
Director of Hepatology
University of California at San Diego
La Jolla, California

Rohit Loomba, MD, MHSc, has disclosed that he has received consulting fees from Alnylam, Arrowhead, Galmed, Gilead Sciences, Janssen, Tobira, and Zafgen; has received funds for research support from Daiichi Sankyo, Galectin, Galmed, Gilead Sciences, Immuron, Merck, and Promedior; and has ownership interest in and a receipt of intellectual property rights/patent holder relationship with Liponexus.
 

Staff

Zachary Schwartz, MSc, ELS


Managing Editor

Zachary Schwartz, MSc, ELS, has no real or apparent conflicts of interest to report.
 

Megan K. Murphy, PhD


Clinical Editor

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.
 

Jenny Schulz, PhD


Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Target Audience

This program is intended for hepatologists, gastroenterologists, and other healthcare providers who care for patients with or at risk for NASH.


Goal

The goal of this activity is to improve participants’ competence in identifying and managing patients with NASH.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Consider key risk factors for development of NAFLD and the pathophysiologic mechanisms that lead to NASH
  • Identify patients at risk for NASH and employ appropriate testing strategies to confirm diagnosis
  • Critically evaluate data on emerging therapies for NASH, including evidence of reversal of fibrosis, safety data, and their potential utility in the treatment of patients with NASH
 

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Commercial Support


This program is supported by an educational grant from Gilead Sciences, Inc..

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 20, 2017, through November 19, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.